公开(公告)号：US07364737B2

公开(公告)日：2008-04-29

申请号：US10768952

申请日：2004-01-29

Applicant: Dennis R. Burton ,  Carlos F. Barbas, III ,  Robert M. Chanock ,  Brian R. Murphy ,  James E. Crowe, Jr.

Inventor： Dennis R. Burton ,  Carlos F. Barbas, III ,  Robert M. Chanock ,  Brian R. Murphy ,  James E. Crowe, Jr.

IPC: A61K39/395 ,  A61K39/42 ,  C07K16/08

CPC classification number: A61K51/1006 ,  A61K38/00 ,  C07K16/1027 ,  C07K2319/00 ,  Y10S424/80 ,  Y10S424/801 ,  Y10S424/809 ,  Y10S530/866 ,  Y10S530/867

Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.

Abstract translation: 公开了结合，中和并对呼吸道合胞病毒（RSV）抗原亚组A和B进行被动免疫治疗的人单克隆抗体及其片段。 还公开了使用单克隆抗体以及产生单克隆抗体的细胞系的诊断和免疫治疗方法。

公开(公告)号：US4704275A

公开(公告)日：1987-11-03

申请号：US769074

申请日：1985-08-26

Applicant: Richard G. Wyatt ,  Albert Z. Kapikian ,  Robert M. Chanock ,  Karen Midthun ,  Jorge Flores ,  Yasutaka Hoshino

Inventor： Richard G. Wyatt ,  Albert Z. Kapikian ,  Robert M. Chanock ,  Karen Midthun ,  Jorge Flores ,  Yasutaka Hoshino

IPC: A61K39/15 ,  A61K39/12

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/575 ,  C12N2720/12334

Abstract: The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.

公开(公告)号：US08778671B2

公开(公告)日：2014-07-15

申请号：US10871775

申请日：2004-06-18

Applicant: Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney, Jr.

Inventor： Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney, Jr.

IPC: C07H21/04 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24143 ,  C12N2770/24162 ,  C12Q1/6888 ,  Y02A50/386 ,  Y02A50/394

Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

Abstract translation: 本发明涉及建立在用于产生免疫原性，活的，减毒的西尼罗病毒疫苗的登革病毒骨架上的减毒，免疫原性的西尼罗病毒嵌合体。

公开(公告)号：US6117667A

公开(公告)日：2000-09-12

申请号：US336740

申请日：1999-06-21

Applicant: Louis Potash ,  Robert M. Chanock ,  Robert H. Purcell ,  Albert Z. Kapikian

Inventor： Louis Potash ,  Robert M. Chanock ,  Robert H. Purcell ,  Albert Z. Kapikian

IPC: C12N5/00 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/15 ,  A61K39/29 ,  A61P31/12 ,  C12N7/00 ,  C12N7/04 ,  C12N7/02

CPC classification number: C12N7/00 ,  A61K39/12 ,  C12N2720/12351 ,  C12N2740/10051 ,  C12N2740/14051 ,  C12N2760/16151 ,  C12N2760/16251 ,  C12N2760/18551 ,  C12N2760/18651 ,  C12N2760/18751 ,  C12N2770/12051 ,  C12N2770/32351 ,  C12N2770/32451 ,  C12N2770/32651

Abstract: The invention described herein provides a method for selecting a novel African Green monkey kidney (AGMK) cell substrate, its cultivation and serial passage and its subsequent characterization. The invention provides a method for the use of the cell substrate in the isolation, growth and serial passage of a large number of viruses, particularly rotaviruses, enteroviruses, respiratory viruses and hepatitis A virus. The invention provides a method for the utilization of this AGMK cell substrate for the production of live and killed virus vaccines.

Abstract translation: 本文描述的本发明提供了一种选择新型非洲绿猴肾（AGMK）细胞底物的方法，其培养和连续传代及其随后的表征。 本发明提供了在大量病毒，特别是轮状病毒，肠道病毒，呼吸道病毒和甲型肝炎病毒的分离，生长和连续传代中使用细胞底物的方法。 本发明提供了一种利用该AGMK细胞底物生产活的和杀死的病毒疫苗的方法。

公开(公告)号：US5646033A

公开(公告)日：1997-07-08

申请号：US351079

申请日：1994-11-30

Applicant: Louis Potash ,  Robert M. Chanock ,  Robert H. Purcell ,  Albert Z. Kapikian

Inventor： Louis Potash ,  Robert M. Chanock ,  Robert H. Purcell ,  Albert Z. Kapikian

IPC: C12N5/00 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/15 ,  A61K39/29 ,  A61P31/12 ,  C12N7/00 ,  C12N7/04 ,  C12N5/06

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N2720/12334 ,  C12N2720/12351 ,  C12N2740/10051 ,  C12N2740/14051 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16234 ,  C12N2760/16251 ,  C12N2760/18534 ,  C12N2760/18551 ,  C12N2760/18634 ,  C12N2760/18651 ,  C12N2760/18734 ,  C12N2760/18751 ,  C12N2770/12034 ,  C12N2770/12051 ,  C12N2770/32334 ,  C12N2770/32351 ,  C12N2770/32434 ,  C12N2770/32451 ,  C12N2770/32634 ,  C12N2770/32651

Abstract: A novel African Green Monkey Kidney (AGMK) cell line is taught as well as a method for the preparation thereof. The cell line which is free of viable adventitious microbial agents is useful as a substrate for viruses and for the preparation of viral vaccines.

Abstract translation: 教授了一种新型的非洲绿猴肾细胞（AGMK）细胞系以及其制备方法。 没有活的不定性微生物剂的细胞系可用作病毒的底物和用于制备病毒疫苗。

公开(公告)号：US4571385A

公开(公告)日：1986-02-18

申请号：US508323

申请日：1983-06-27

Applicant: Harry B. Greenberg ,  Richard G. Wyatt ,  Albert Z. Kapikian ,  Anthony R. Kalica ,  Karen Midthun ,  Robert M. Chanock

Inventor： Harry B. Greenberg ,  Richard G. Wyatt ,  Albert Z. Kapikian ,  Anthony R. Kalica ,  Karen Midthun ,  Robert M. Chanock

IPC: C12N15/00 ,  A61K39/00 ,  A61K39/15 ,  A61P31/12 ,  C12N7/00 ,  C12N7/04 ,  C12N15/02 ,  C12N15/09 ,  C12R1/91 ,  C12N7/08

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/15 ,  C12N2720/12334 ,  C12N2720/12361

Abstract: This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.

Abstract translation: 本发明涉及用于产生，分离和表征人轮状病毒/动物轮状病毒重配体并产生活减毒疫苗和疫苗前体的方法。 在本策略中，涉及新使用（1）高滴度超免疫抗血清或（2）单克隆抗血清来选择具有所需人表型的重配。 一个新颖的观点是单独的抗血清或单克隆抗血清的发现，只要其具有针对34-38Kd糖蛋白或动物亲本的高滴度中和活性，足以用于选择具有人表型的重配轮状病毒。 此外，新产品是减毒活疫苗的前体和疫苗。

公开(公告)号：US08168202B2

公开(公告)日：2012-05-01

申请号：US11994640

申请日：2006-07-07

Applicant: Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Mary Elaine La Montagne, legal representative ,  Brian R. Murphy

Inventor： Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Brian R. Murphy

IPC: A61K39/15

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/70 ,  C12N2720/12334

Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Abstract translation: 本发明提供了用于防止设计用于世界特定地区的人类轮状病毒病的疫苗组合物。 将包含人轮状病毒的四种临床上最重要的VP7血清型中的每一种的人×牛重配轮状病毒与通常在感兴趣区域中发现的其它VP7血清型组合成多价制剂，其提供高度的感染性和免疫原性。 还提供了用于产生免疫原性反应而不产生增加的肠套叠风险的方法和管理方案。

公开(公告)号：US20120087909A1

公开(公告)日：2012-04-12

申请号：US13250357

申请日：2011-09-30

Applicant: Glenn R. Pilkington ,  Page S. Gilmour ,  Robert M. Chanock ,  James E. Crowe, JR. ,  Brian R. Murphy

Inventor： Glenn R. Pilkington ,  Page S. Gilmour ,  Robert M. Chanock ,  James E. Crowe, JR. ,  Brian R. Murphy

IPC: A61K39/395

CPC classification number: C07K16/1027 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61K51/1006 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  G01N33/56983

Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.

Abstract translation: 本发明涉及鉴定和克隆呼吸道合胞病毒的新型中和人单克隆抗体。 本发明提供了这样的抗体，保留RSV结合能力的这些抗体片段，保留RSV结合能力的嵌合抗体以及包含这种抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 最后，本发明提供了使用本发明的抗体和核酸的诊断和治疗方法。

公开(公告)号：US06794174B2

公开(公告)日：2004-09-21

申请号：US10207745

申请日：2002-07-26

Applicant: Alexander Pletnev ,  Robert M. Chanock

Inventor： Alexander Pletnev ,  Robert M. Chanock

IPC: C12N701

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/24164

Abstract: Embodiments described herein include full-length infectious cDNA clones of Langat tick-borne flavivirus.

Abstract translation: 本文描述的实施方案包括Langat蜱传黄色病毒的全长感染性cDNA克隆。

公开(公告)号：US06685942B1

公开(公告)日：2004-02-03

申请号：US08920100

申请日：1997-08-26

Applicant: Dennis R. Burton ,  Carlos F. Barbas, III ,  Robert M. Chanock ,  Brian R. Murphy ,  James E. Crowe, Jr.

Inventor： Dennis R. Burton ,  Carlos F. Barbas, III ,  Robert M. Chanock ,  Brian R. Murphy ,  James E. Crowe, Jr.

IPC: A61K39395

CPC classification number: A61K51/1006 ,  A61K38/00 ,  C07K16/1027 ,  C07K2319/00 ,  Y10S424/80 ,  Y10S424/801 ,  Y10S424/809 ,  Y10S530/866 ,  Y10S530/867

Abstract: A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.

Abstract translation: 公开了一种在宿主中为呼吸道合胞病毒（RSV）疾病提供被动免疫疗法的方法。 该方法包括向宿主施用中和呼吸道合胞病毒（RSV）的抗原亚组A和亚组B的人单克隆抗体Fab片段或包含该片段的单克隆抗体。